Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Uncertainty: Overview00:59

Uncertainty: Overview

In analytical chemistry, we often perform repetitive measurements to detect and minimize inaccuracies caused by both determinate and indeterminate errors. Despite the cares we take, the presence of random errors means that repeated measurements almost never have exactly the same magnitude. The collective difference between these measurements - observed values - and the estimated or expected value is called uncertainty. Uncertainty is conventionally written after the estimated or expected value.
Propagation of Uncertainty from Random Error00:59

Propagation of Uncertainty from Random Error

An experiment often consists of more than a single step. In this case, measurements at each step give rise to uncertainty. Because the measurements occur in successive steps, the uncertainty in one step necessarily contributes to that in the subsequent step. As we perform statistical analysis on these types of experiments, we must learn to account for the propagation of uncertainty from one step to the next. The propagation of uncertainty depends on the type of arithmetic operation performed on...
Uncertainty: Confidence Intervals00:54

Uncertainty: Confidence Intervals

The confidence interval is the range of values around the mean that contains the true mean. It is expressed as a probability percentage. The interpretation of a 95% confidence interval, for instance, is that the statistician is 95% confident that the true mean falls within the interval. The upper and lower limits of this range are known as confidence limits. The confidence limits for the true mean are estimated from the sample's mean, the standard deviation, and the statistical factor 't,' or...
Decision Making: P-value Method01:09

Decision Making: P-value Method

The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health costs of the UK-US trade deal on pharmaceuticals.

BMJ (Clinical research ed.)·2026
Same author

Insights from Financial Economics to Value Healthcare Investments that Reduce System-Level Risks: Example of Disease Elimination and Eradication.

Applied health economics and health policy·2026
Same author

Alternative Pricing Policies for Multi-Indication Products: A Quantitative Analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Equitable access to costly new drugs.

BMJ (Clinical research ed.)·2025
Same author

Is Caring Productive? The Effect of Adult Social Care on Paid Production in England.

Health economics·2025
Same author

Guiding Health Resource Allocation: Using Population Net Health Benefit to Align Disease Burden with Cost Effectiveness for Informed Decision Making.

Applied health economics and health policy·2025
Same journal

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.

PharmacoEconomics·2026
Same journal

Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update.

PharmacoEconomics·2026
Same journal

Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment.

PharmacoEconomics·2026
Same journal

A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.

PharmacoEconomics·2026
Same journal

Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.

PharmacoEconomics·2026
Same journal

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Exploring uncertainty in cost-effectiveness analysis.

Karl Claxton1

  • 1Centre for Health Economics, Department of Economics and NICE Decision Support Unit, University of York, Heslington, York, UK. kpc1@york.ac.uk

Pharmacoeconomics
|September 5, 2008
PubMed
Summary
This summary is machine-generated.

Assessing uncertainty is crucial for health technology assessment decisions. This paper explores formal methods to improve how the UK National Institute for Health and Clinical Excellence (NICE) evaluates uncertainty and its impact on healthcare recommendations.

More Related Videos

Experimental Research Examining How People Can Cope with Uncertainty Through Soft Haptic Sensations
09:07

Experimental Research Examining How People Can Cope with Uncertainty Through Soft Haptic Sensations

Published on: September 16, 2015

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

Related Experiment Videos

Last Updated: Jul 2, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Experimental Research Examining How People Can Cope with Uncertainty Through Soft Haptic Sensations
09:07

Experimental Research Examining How People Can Cope with Uncertainty Through Soft Haptic Sensations

Published on: September 16, 2015

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

Area of Science:

  • Health Technology Assessment
  • Decision Analysis
  • Evidence-Based Medicine

Background:

  • Decisions by bodies like the UK National Institute for Health and Clinical Excellence (NICE) require rigorous assessment of uncertainty.
  • Uncertainty impacts the reliability and applicability of health technology assessments.

Purpose of the Study:

  • To outline the critical principles of uncertainty assessment in decision-making for health bodies.
  • To evaluate the utility of formal methods for NICE in assessing parameter and other uncertainties.
  • To guide the selection of appropriate methods for representing and communicating uncertainty.

Main Methods:

  • Discussion of probabilistic sensitivity analysis (PSA) for parameter uncertainty.
  • Exploration of methods for representing diverse sources of uncertainty.
  • Consideration of computational expense versus the necessity of expressing uncertainty.
  • Review of summary measures for presenting uncertainty to decision-makers.
  • Assessment of formal methods for evidence needs and decision consequences.

Main Results:

  • Probabilistic sensitivity analysis remains a recommended method for parameter uncertainty.
  • Various methods exist for representing different uncertainty types, requiring careful selection.
  • Computational cost should not preclude the expression of uncertainty.
  • Appropriate summary measures are vital for effective communication to decision-makers.
  • Formal methods can inform evidence needs and the consequences of uncertain decisions.

Conclusions:

  • Formal methods offer valuable tools for NICE to enhance the assessment of uncertainty in health technology evaluations.
  • Improved methods for representing and communicating uncertainty are essential for robust decision-making within the UK NHS.
  • A systematic approach to uncertainty assessment strengthens evidence-based healthcare policy.